Clinical Trial Update: First Real-world Data on Unresectable Stage III NSCLC Patients Treated With Durvalumab After Chemoradiotherapy

View source ↗

Summary

This update presents the first real-world data on the use of durvalumab after chemoradiotherapy in patients with unresectable stage III non-small cell lung canc…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• IMFINZI (DURVALUMAB)

Snippet

Sponsor: AstraZeneca | Conditions: NSCLC | Status: COMPLETED